Literature DB >> 9215324

Octreotide and lanreotide treatment in active acromegaly.

S Cannavò, R Fazio, S Squadrito, F Trimarchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9215324

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  2 in total

1.  Lanreotide autogel is a therapeutic option for patients who develop acute pancreatitis after somatostatin analog treatment.

Authors:  E Boix; P López; M Pérez-Mateo; A Picó
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

2.  Octreotide-periplocymarin conjugate prodrug for improving targetability and anti-tumor efficiency: synthesis, in vitro and in vivo evaluation.

Authors:  Hui-Yun Zhang; Wen-Qian Xu; Yuan-Yuan Zheng; Emmanuel Omari-Siaw; Yuan Zhu; Xia Cao; Shan-Shan Tong; Jiang-Nan Yu; Xi-Ming Xu
Journal:  Oncotarget       Date:  2016-12-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.